Amicus Therapeutics, Inc. (FOLD)
NASDAQ: FOLD · Real-Time Price · USD
9.46
+0.10 (1.07%)
At close: Jan 8, 2025, 4:00 PM
9.47
+0.01 (0.11%)
Pre-market: Jan 10, 2025, 4:12 AM EST
Amicus Therapeutics Stock Forecast
Stock Price Forecast
The 7 analysts with 12-month price forecasts for Amicus Therapeutics stock have an average target of 17, with a low estimate of 12 and a high estimate of 21. The average target predicts an increase of 79.70% from the current stock price of 9.46.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for FOLD stock from 8 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jul '24 | Aug '24 | Sep '24 | Oct '24 | Nov '24 | Dec '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 4 | 4 | 4 | 4 |
| Buy | 3 | 3 | 3 | 3 | 3 | 2 |
| Hold | 2 | 2 | 2 | 2 | 1 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 8 | 8 | 9 | 9 | 8 | 8 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Morgan Stanley | Morgan Stanley | Buy → Hold Downgrades $17 → $12 | Buy → Hold | Downgrades | $17 → $12 | +26.85% | Dec 13, 2024 |
| JP Morgan | JP Morgan | Buy Maintains $16 → $17 | Buy | Maintains | $16 → $17 | +79.70% | Nov 12, 2024 |
| UBS | UBS | Strong Buy Maintains $19 → $21 | Strong Buy | Maintains | $19 → $21 | +121.99% | Nov 7, 2024 |
| Guggenheim | Guggenheim | Strong Buy Maintains $13 → $15 | Strong Buy | Maintains | $13 → $15 | +58.56% | Nov 7, 2024 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Maintains $20 → $21 | Buy | Maintains | $20 → $21 | +121.99% | Nov 7, 2024 |
Financial Forecast
Revenue This Year
536.46M
from 399.36M
Increased by 34.33%
Revenue Next Year
652.85M
from 536.46M
Increased by 21.70%
EPS This Year
-0.20
from -0.51
EPS Next Year
0.15
from -0.20
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 554.3M | 717.1M | 928.0M | |||
| Avg | 536.5M | 652.9M | 809.6M | |||
| Low | 513.8M | 601.9M | 700.4M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 38.8% | 33.7% | 42.1% | |||
| Avg | 34.3% | 21.7% | 24.0% | |||
| Low | 28.7% | 12.2% | 7.3% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | -0.12 | 0.37 | 0.80 | |||
| Avg | -0.20 | 0.15 | 0.52 | |||
| Low | -0.25 | 0.02 | 0.36 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | - | - | 435.9% | |||
| Avg | - | - | 246.4% | |||
| Low | - | - | 143.5% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.